CC
DCPH

Casdin Capital’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Casdin Capital’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-65,000
Closed -$3.33M – 55
2020
Q3 		$3.33M Hold
65,000
– – 0.15% 45
2020
Q2 		$3.88M Sell
65,000
-75,000
-54% -$4.01M 0.23% 41
2020
Q1 		$5.76M Sell
140,000
-115,000
-45% -$6.39M 0.61% 35
2019
Q4 		$15.9M Buy
255,000
+155,000
+155% +$7.37M 1.46% 23
2019
Q3 		$3.39M Buy
+100,000
New +$2.96M 0.35% 31

Other funds holding DCPH

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Casdin Capital's DCPH Position: Q4 2020 in Review

Casdin Capital sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q4 2020, closing a stake of 65,000 shares — an estimated $3.33M sold.

Casdin Capital first reported a position in DCPH in Q3 2019 and held it in 5 quarters. The position peaked at $15.9M in Q4 2019. 182 funds tracked by Wall St. Rank hold DCPH as of Q4 2020.

  • Casdin Capital reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Casdin Capital sold 65,000 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q4 2020, an estimated $3.33M.
  • Casdin Capital first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 5 quarters.
  • Casdin Capital's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $15.9M in Q4 2019.
  • 182 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q4 2020.

Based on Casdin Capital's 13F filing for Q4 2020, filed 16 Feb 2021.